Clinical Trial Update: Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG [Phase 2]

View source ↗

Summary

A Phase 2 study of the MEK inhibitor binimetinib plus the BRAF inhibitor encorafenib in adults with recurrent BRAF V600-mutant high-grade gliomas was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Pleomorphic Xanthoastrocytoma
• Glioblastoma
• Gliosarcoma
• High-grade Glioma

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: High Grade Glioma, BRAF V600E | Phase 2 | Status: TERMINATED | Results posted: 2024-03-06